NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 10 PAGES Amendment No. 21

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

1.	Lice Alliance HealthCare Ser	September 16, 2019.	piration Date: September 30, 2021
2.	330 Harper Park Drive, Beckley, WV 25801		ocket No.: 030-35774 eference No.:
6.	Byproduct, source, and/or special nuclear material	 Chemical and/or physical form 8. Maximum amount that licensee may possess at any one time under this license 	9. Authorized use
A.	Any byproduct material permitted by 10 CFR 35.200	A. As Needed	A. For use in imaging and localization studies permitted by 10 CFR 35.200.
В.	Strontium-82	B. Any Except Sealed Sources B. 200 millicuries total	B. For decay in storage only in accordance with 10 CFR 35.92.
C.	Strontium-85	C. Any Except Sealed Sources C. 1 curie total	C. For decay in storage only in accordance with 10 CFR 35.92.
D.	Germanium-68	D. Sealed Sources	 For storage only, limited to one year, incident to transfer in accordance with 10 CFR 30.41.
		CONDITIONS	

NRC FORM 374A	U.S. NUCLEAR REGULA	ATORY COMMISSION	PAGE 2 OF 10 PAGES		
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774			
SUPPLEMENTARY SHEET	Amendment No. 21				
 10. A. Licensed material listed in Subitem No. 6.A. incident to mobile nuclear medicine activities may be used or stored at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States. If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the Federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency. B. Licensed material listed in Subitem Nos. 6.B and 6.C., limited to strontium waste generated incident to mobile nuclear medicine activities, may be stored at the licensee's facilities located at 525 S. Gould Street, Owasso, Michigan, for decay in storage in accordance with 10 CFR 35.92. C. Licensed material listed in Subitem No. 6.D., limited to germanium 68 sealed sources transferred from the licensee's mobile nuclear medicine vans, may be stored at the licensee's facilities located at 525 S. Gould Street, Owasso, Michigan, for up to one year pending transfer to an authorized recipient in accordance with 10 CFR 30.41. 					
11. Licensed material shall only be used by	r, or under the supervision of:				
A. Individuals permitted to work as an	authorized user in accordance	with 10 CFR 35.13 and 10 CFR 35.14			
B. The following individuals are author	rized users for the material and	medical uses as indicated:			
Authorized User(M.D.,D.O.,etc.)	Material and Use				
David Abramowitz, M.D.	10 CFR 35.200				
Irfan Ahmad, M.D.	10 CFR 35.200				
Afzal Ahmed, M.D.	10 CFR 35.200				
Mark J. Akers, M.D.	10 CFR 35.200				
Paul D. Akers, M.D.	10 CFR 35.200				
Paul J. Alfieri, M.D.	10 CFR 35.200				

.

NRC FORM 374A	U.S. NUCLEAR REGULATO	DRY COMMISSION	PAGE 3 OF 10 PAGES
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774	
SUPPLEMENTARY SHEET	Amendment No. 21		
Authorized User(M.D.,D.O.,etc.)	Material and Use		
Syed I. Ali, M.D.	10 CFR 35.200		
Marsha Anderson, M.D.	10 CFR 35.200	T. E.F.	
Ibad U. Ansari, M.D.	10 CFR 35.200		
James Baek, M.D.	10 CFR 35.200	FULANDA	
Indraneel Banerji, M.D.	10 CFR 35.200	Stand Stand	
Marc R. Beck, M.D.	2010 CFR 35.200	Jam -	
Martin Black, M.D.	10 CFR 35.200		
Richard R. Black, D.O.	10 CFR 35.200		
Rodger Blake, M.D.	10 CFR 35.200	N C S S S S S S S S S S S S S S S S S S	
Paul H. Blom, M.D.	10 CFR 35.200	n and a second sec	
Robert L. Bridges, M.D.	10 CFR 35.200		
James M. Browne, M.D.	10 CFR 35.200		
Douglas A. Bruns, D.O.	10 CFR 35.200	E. S.	
James Paul Carl, M.D.	10 CFR 35.200	<u></u>	
Christopher Carrel, M.D.	10 CFR 35.200	A CONTRACT OF A CONTRACT.	
Peter Chirico, M.D.	10 CFR 35 200		
Jesse A. Cole, M.D.	10 CFR 35.200	- () · · · · · · · · · · · · · · · · · ·	
Ricky J. Compton, M.D.	10 CFR 35.200		
John Phillip Cox, D.O.	10 CFR 35.200		
Robert J. Cure, M.D.	10 CFR 35.200		
Michael T. Czuba, M.D.	10 CFR 35.200		
Ryan Daily, M.D.	10 CFR 35.200		
Corinne Daurdulian, M.D.	10 CFR 35.200		
Edward Dentsman, M.D.	10 CFR 35.200		

NRC FORM 374A	NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 OF 10 PAGES				
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774			
SUPPLEMENTARY SHEET	Amendment No. 21				
		1			
Authorized User(M.D.,D.O.,etc.)	Material and Use				
Vu Quoc Do, M.D.	10 CFR 35.200				
Hans G. Dransfeld, M.D.	10 CFR 35.200				
Joseph Dransfeld, M.D.	10 GFR 35.200	< x			
Nathaniel D. Dueker, M.D.	10 CFR 35.200				
Adwoa Essel, M.D.	10 CFR 35.200				
Joshua Dale Gibson, M.D.	う 10 CFR 35.200	June			
Lee Corey Haikal, M.D.	10 CFR 35.200				
Nathan R. Hatfield, M.D.	10 CFR 35.200				
Mark R. Heitzman, M.D.	10 CFR 35.200				
Prasanta K. Karak, M.D.	10 CFR 35.200	Provide and the second			
Kastytis C. Karvelis, M.D.	10 CFR 35.200	and the second s			
Stephen Joowhan Kim, M.D.	10 CFR 35.200	Con			
Philip Kohanski, M.D.	10 CFR 35.200				
Michael V. Korona, Jr., M.D.	10 CFR 35.200				
Gary W. Kravetz, M.D.	10 CFR 35.200				
Adam Thomas Krompecher, M.D.	10 CFR 35 200				
Benjamin Lange, M.D.	10 CFR 35.200				
Christopher J. Leary, M.D.	10 CFR 35.200				
Eric Lawrence Leonard, M.D.	10 CFR 35.200				
Donald Lewis, M.D.	10 CFR 35.200				
Edward J. Maas, M.D.	10 CFR 35.200				
Colleen M. Madden, M.D.	10 CFR 35.200				
Jane MaLoof, M.D.	10 CFR 35.200				
Jack D. Markiewicz, M.D.	10 CFR 35.200				

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 5 OF 10 PAGES				
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774		
SUPPLEMENTARY SHEET	Amendment No. 21			
Authorized User(M.D.,D.O.,etc.)	Material and Use			
Matthew E. Maxwell, M.D.	10 CFR 35.200			
Timothy J. McCue, M.D.	10 CFR 35,200			
Chris W. McGary, M.D.	10 GFR 35.200			
Russell Meyer, M.D.	10 CFR 35.200 10 CFR 35.200	NA X		
Khalid A. Mian, M.D.	40 CFR 35.200	1927 p.		
Thomas E. Miller, M.D. Steve Min, D.O.	10 CFR 35.200			
Daniel R. Mitchell, M.D.	10 CFR 35.200	n film film film film film film film film		
Virginia Molleran, M.D.	10 CFR 35.200	n an		
Craig Moore, M.D.	10 CFR 35.200			
Jaochim Mueller, M.D.	10 CFR 35.200	And a second sec		
AppaRao Mukkamala, M.D.	2 10 CFR 35.200	2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 2004 - 		
Joshua A. Nepute, M.D.	10 CFR 35.200			
Dana Olson, M.D.	10 CFR 35.200			
Marlo M. Pagano, M.D.	10 CFR 35.200	A Contraction of the second se		
Charles Nicholas Pappas, M.D.	10 CFR 35 200			
Samir Parikh, M.D.	10 CFR 35.200			
Bharat Patel, M.D.	10 CFR 35.200			
Joseph Pekala, M.D.	10 CFR 35.200			
Mark Peterson, M.D.	10 CFR 35.200			
Grant D. Petty, M.D.	10 CFR 35.200			
Krishna R. Pillai, M.D.	10 CFR 35.200			
James Milton Reynolds, M.D.	10 CFR 35.200			
Sean Reynolds, M.D.	10 CFR 35.200			

FORM 374A	U.S. NUCLEAR REGULATO	RY COMMISSION	PAGE 6 OF 10 PAGES
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774	
SUPPLEMENTARY SHEET	Amendment No. 21		
Authorized User(M.D.,D.O.,etc.)	Material and Use		
Michael E. Robertello, M.D.	10 CFR 35.200		
Ruben Rock, M.D.	10 CFR 35,200	Plex	
Daniel Adam Rodgers, M.D.	10 CFR 35.200		
Colin Rose, M.D.	10 CFR 35.200		
Heather Rose, M.D.	10 CFR 35.200		
Ronald J. Rosenberg, M.D.	10 CFR 35.200	e free	
Robert M. Salman, M.D.	10 CFR 35.200		
Paul Sanchirico, M.D.	10 CFR 35.200		
Gerling Sauter, M.D.	10 CFR 35.200	a de la companya de la compa	
Charles Seigler, M.D.	10 CFR 35.200	n de la composición de La composición de la c	
Marc A. Seltzer, M.D.	10 CFR 35.200	and the second se	
Mark Shaman, M.D.	10 CFR 35.200	in the second	
Stanley M. Shapiro, M.D.	10 CFR 35.200		
Paul W. Sheets, M.D.	10 CFR 35.200		
Paul D. Shreve, M.D.	10 CFR 35.200		
Ralph E. Shrider, M.D.	10 CFR 35:200		
Alan Siegel, M.D.	10 CFR 35.200		
Justin Sims, M.D.	10 CFR 35.200		
Roshan Sivagnanam, M.D.	10 CFR 35.200		
LeAnn Stidham, M.D.	10 CFR 35.200		
Victoria A. Swegles, D.O.	10 CFR 35.200		
Sanjay J. Talati, M.D.	10 CFR 35.200		
Smari Thordarson, M.D.	10 CFR 35.200		
Walter Parke Thrush, M.D.	10 CFR 35.200		

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMM	IISSION PAGE 7 OF 10 PAGES	
MATERIALS LICENSE		License Number 47-25570-01	Docket or Reference Number 030-35774	
	SUPPLEMENTARY SHEET	Amendment No. 21		
	Authorized User(M.D.,D.O.,etc.)	Material and Use		
	Boguslaw Uchman, M.D.	10 CFR 35.200		
	Matthew Waack, M.D.	10 CFR 35.200 10 CFR 35.200 10 CFR 35.200 10 CFR 35.200 10 CFR 35.200 10 CFR 35.200		
	Torin P. Walters, M.D.	10 CFR 35.200		
	James K. Watson, M.D.	10 CFR 35.200		
	Jonathan W. Weiss, M.D.	10 CFR 35.200		
	Ehab Hassan A. Youssef, MBBCH,	2 10 CFR 35.200		
	M.D.	ير در المراجع المراجع المراجع المراجع المراجع المراجع		
15.	 M.D. 2. The Radiation Safety Officer for this license is Kay Kassel, M.S., C.N.M.T. 3. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance. 4. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory. 			

NRC FORM	M 374A	U.S. NUCLEAR REGULATORY COMM	ISSION PAGE 8 OF 10 PAGES		
	MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774		
	SUPPLEMENTARY SHEET	Amendment No. 21			
В.	registration issued by the U.S. Nuclea	•	been made within the intervals specified in the certificate of R 32.210 or by an Agreement State, prior to the transfer, a ited and the test results received.		
C.		nore than 100 microcuries of beta- and/o	ontain only a radioactive gas; or the half-life of the isotope is r gamma-emitting material or not more than 10		
D.	D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.				
E.	E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microeuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.				
F.	•		and analysis, shall be performed by the licensee or other an Agreement State to perform such services.		
G.	Records of leak test results shall be l	kept in units of becquerels (microcuries)	and shall be maintained for 3 years.		

NRC FORM 374A	U.S. NUCLEAR REGULATORY COM	IISSION PAGE 9 OF 10 PAGES
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774
SUPPLEMENTARY SHEET	Amendment No. 21	
representations, and procedures contain those procedures that are required to be licensee's ability to make changes to the	ed in the documents, including any/encl submitted in accordance with the regula radiation protection program as provide nless the statements, representations, a n the regulations. 0970462] 440261] A190] 292A554] 22A219] 022A229]	act its program in accordance with the statements, osures, listed below. This license condition applies only to ations. Additionally, this license condition does not limit the d for in 10 CFR 35.26. The U.S. Nuclear Regulatory and procedures in the licensee's application and

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMI	SSION	PAGE 10 OF 10 PAGES
MATERIALS LICENSE	License Number 47-25570-01	Docket or Reference Number 030-35774	
SUPPLEMENTARY SHEET	Amendment No. 21		
continued			
H. Letter dated August 31, 2018 (delegati			
I. Letter dated September 16, 2019 [ML19 J. Letter received November 5, 2019 [ML			
		le l	
		· (\$	
		a na serie a construction de la	
		an and a second se	
		<u>S</u>	
	iner Stran		
		Ser and a series of the series	
	A THE THE AS		
	FOR	THE U.S. NUCLEAR REGULATOR	COMMISSION
Date: December 16, 2019	By: _	Maria	
	R	enny Lanzisera egion 1	